Terlipressin

Terlipressin
Clinical data
Trade names	Terlivaz
AHFS/Drugs.com	International Drug Names
Routes of; administration	Intravenous
ATC code	H01BA04 (WHO) ;
Legal status
Legal status	US: ℞-only;
Pharmacokinetic data
Protein binding	~30%
Identifiers
	IUPAC name 1-{[(4R,7S,10S,13S,16S,19R)-19-{[({[(aminoacetyl)amino]acetyl}amino)acetyl]amino}-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-(4-hydroxybenzyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl]carbonyl}-L-prolyl-N-(2-amino-2-oxoethyl)-L-lysinamide;
CAS Number	14636-12-5 ;
PubChem CID	72081;
DrugBank	DB02638 ;
ChemSpider	65067 ;
UNII	7Z5X49W53P;
KEGG	D06672 ;
CompTox Dashboard (EPA)	DTXSID7048952 ;
ECHA InfoCard	100.035.149
Chemical and physical data
Formula	C52H74N16O15S2
Molar mass	1227.38 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(N)CNC(=O)[C@@H](NC(=O)[C@H]4N(C(=O)[C@H]1NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CN)CSSC1)Cc2ccc(O)cc2)Cc3ccccc3)CCC(=O)N)CC(=O)N)CCC4)CCCCN;
	InChI InChI=1S/C52H74N16O15S2/c53-17-5-4-9-31(45(76)60-23-41(57)72)63-51(82)38-10-6-18-68(38)52(83)37-27-85-84-26-36(61-44(75)25-59-43(74)24-58-42(73)22-54)50(81)65-34(20-29-11-13-30(69)14-12-29)48(79)64-33(19-28-7-2-1-3-8-28)47(78)62-32(15-16-39(55)70)46(77)66-35(21-40(56)71)49(80)67-37/h1-3,7-8,11-14,31-38,69H,4-6,9-10,15-27,53-54H2,(H2,55,70)(H2,56,71)(H2,57,72)(H,58,73)(H,59,74)(H,60,76)(H,61,75)(H,62,78)(H,63,82)(H,64,79)(H,65,81)(H,66,77)(H,67,80)/t31-,32-,33-,34-,35-,36-,37-,38-/m0/s1 ; Key:BENFXAYNYRLAIU-QSVFAHTRSA-N ;
	(verify)

Terlipressin, sold under the brand name Terlivaz among others, is an analogue of vasopressin used as a vasoactive drug in the management of low blood pressure. It has been found to be effective when norepinephrine does not help. Terlipressin is a vasopressin receptor agonist.^[1]

Terlipressin was approved for medical use in the United States in 2022.^[1]^[3]^[4] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.^[4]^[5]

^ ^a ^b ^c Cite error: The named reference Terlivaz FDA label was invoked but never defined (see the help page).
^ "Drug Approval Package: Terlivaz". U.S. Food and Drug Administration (FDA). 7 October 2022. Retrieved 4 December 2022.
^ "Drug Approval Package: Terlivaz". U.S. Food and Drug Administration (FDA). 7 October 2022. Archived from the original on December 4, 2022. Retrieved 23 January 2023.
^ ^a ^b "Advancing Health Through Innovation: New Drug Therapy Approvals 2022". U.S. Food and Drug Administration (FDA). 10 January 2023. Archived from the original on January 10, 2023. Retrieved 22 January 2023. This article incorporates text from this source, which is in the public domain.
^ New Drug Therapy Approvals 2022. U.S. Food and Drug Administration (FDA) (Report). January 2024. Archived from the original (PDF) on 14 January 2024. Retrieved 14 January 2024. This article incorporates text from this source, which is in the public domain.

[Terlivaz_FDA_label-1] Cite error: The named reference Terlivaz FDA label was invoked but never defined (see the help page).

[2] "Drug Approval Package: Terlivaz". U.S. Food and Drug Administration (FDA). 7 October 2022. Retrieved 4 December 2022.

[3] "Drug Approval Package: Terlivaz". U.S. Food and Drug Administration (FDA). 7 October 2022. Archived from the original on December 4, 2022. Retrieved 23 January 2023.

[New_Drug_Therapy_Approvals_2022-4] "Advancing Health Through Innovation: New Drug Therapy Approvals 2022". U.S. Food and Drug Administration (FDA). 10 January 2023. Archived from the original on January 10, 2023. Retrieved 22 January 2023. This article incorporates text from this source, which is in the public domain.

[5] New Drug Therapy Approvals 2022. U.S. Food and Drug Administration (FDA) (Report). January 2024. Archived from the original (PDF) on 14 January 2024. Retrieved 14 January 2024. This article incorporates text from this source, which is in the public domain.

[1]

[2]

[3]

[4]

[5]